CXCL8 and lung carcinoma: Importantly, we show that for patients treated with combination therapy, the specificity and sensitivity of IL-8 and IP10 as predictors were better than those of IL-8 and IP10 alone, which was verified in not only lung cancer but also multiple cancer research cohorts.